studies

778A AASLD ABSTRACTS HEPATOLOGY, October, 2015
Michel Ng - Advisory Committees or Review Panels: abbvie; Speaking and
Teaching: abbvie
Douglas Dieterich - Advisory Committees or Review Panels: Gilead, BMS, Abbvie,
Janssen, Merck, Achillion
Jeffrey J. Weiss - Consulting: AbbVie Inc.
The following authors have nothing to disclose: Ponni V. Perumalswami, Korin
Parrella, Jason Rogers, Rahul Patel, Brooke Wyatt, Brian Kim, Anna Patel, Joseph
Lawler, Alicia Stivala, Donald Gardenier, Catherine Amory, Aaron M. Vanderhoff,
Ashish Atreja
1152
Patient Expectations of the Impact on Quality of Life of
Hepatitis C Treatment
Shelagh M. Szabo 2 , David R. Walker 1 , Timothy R. Juday 1 ,
Suzanne Lane 2 , Adrian Levy 2 , Sammy Saab 3 ; 1 HEOR, Abbvie,
North Chicago, IL; 2 Icon Health Economics, Vancouver, BC, Canada;
3 David Geffen School of Medicine, UCLA, Los Angeles, CA
BACKGROUND The Investigative Multicenter Prospective Observational
Study (IMPROOV) is a study of humanistic and economic
outcomes among patients initiating direct acting antiviral
treatments for hepatitis C virus (HCV). The objective of this analysis
is to describe patient-reported expectations of the impact
on quality of life of newly-initiated HCV treatment. METHODS
All consecutive HCV patients attending clinics at ten sites in
the United States were screened to identify the cohort initiating
treatment for HCV. Data were collected using patient-completed
surveys at up to five time points over the treatment
course, supplemented by a medical chart review at treatment
initiation and completion. Data collected included demographic,
clinical, economic, and humanistic. Data on patients’
expectations of the impact on quality of life of newly-initiated
treatment were collected; multiple responses were allowed per
patient. The specific question asked at baseline was: “Do you
expect the following to occur, when you start HCV treatment”;
and a series of potential patient experiences were listed to
which patients responded with the expected impact. Response
options included: none, a little, moderate or severe. The sum
of patients expecting moderate/severe outcomes was calculated.
First patient enrolled 1/2013 and last patient enrolled
9/2014. RESULTS 143 patients, from 8 clinics, enrolled out
of 787 that were screened across 10 clinics of which 137
were from community clinics and 6 from academic/hospitals.
Mean age was 56 years, 52% male, 60% white, 20% hispanic
and 15% black. 75% graduated from high school and
33% were employed. 100 patients were on a sofosbuvir and/
or simeprevir-based regimen, and 43 patients were on other
treatments. 74 were on an interferon-free (IFF) regimen. The
proportion of patients expecting moderate/severe impacts of
newly initiated treatment for those on IFF and interferon-containing
treatment, respectively, were: treatment-related side-effects
(31.5%, 50.7%;p=0.02), missed work (7.2%,17.9%;p=0.06
), decreased productivity at work (9.9%, 25.0%;p=0.03), limited
social activities (25.0%,40.6%;p=0.05), increased reliance
on family/friends (18.8%,36.2%;p=0.02), impact on
your quality of life (21.4%,49.3%;p